Abbott Labs Completes Purchase of SpectRx Stock
NORCROSS, Ga., Jan. 5 -- Abbott Laboratories has purchased $2.5 million in convertible redeemable preferred stock of SpectRx Inc., bringing Abbott's total purchase of SpectRx stock to $5.25 million. SpectRx reported that the stock purchase was part of an agreement between the two companies to jointly develop a continuous glucose monitor for diabetics. The agreement assigns to Abbott exclusive worldwide marketing rights to continuous monitoring applications and to single-use monitoring applications of the technology. SpectRx will receive a royalty on sales of disposable devices, and will have the option to manufacture continuous monitoring devices for Abbott.
The monitor uses a surface-worn patch containing a glucose sensor -- based on SpectRx's biophotonic technology -- to measure glucose levels in interstitial fluid (ISF). ISF is collected through an array of micropores created with a laser in the
stratum corneum, or dead outer layer of skin. According to SpectRx, prototypes of the device have shown it capable of providing one reading per minute.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024